The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
- Profit for the period of £25.8 million (31 March 2022: £108.9 million) primarily reflects the impact of lower electricity prices compared to the prior period. For further information refer to the financial review below
Ok the profit for HY22 was £108m but HY 21 was only £3.8m... They still paid the dividend then! and the year before.
- Company NAV per ordinary share at 31 March 2023 of 112.24 pence (31 March 2022: 112.75 pence)
NAV remains high. 30% higher then here. Hard to figure out why this has dropped?
Good assessment Trot. Although, thing I can't understand is SP seems to have inverse relationship with interest rates. Perhaps just because rates have only risen inline with energy prices but you'd think the protected nature of the income from an inflationary environment would be attractive (unless of course all bond default). Still, seems oversold and I am buying at these levels
£30 mil market cap with £390m in funding, asset rich just got to pull the stuff out the ground. No ones throwing £390 at a project unless extraction is guaranteed. £390m that lenders are expecting to get back with interest. Minimum 10x on this and we wont be waiting years for it. Market will wake up soon
I've a contact in Ethiopia, said KEFI is all over the news there. Government very excited about KEFI prospects. Can't lose on this one boys. Going to £6 in 2 years, there's that much gold in the ground lol